Inhibrx Biosciencesincis A Clinical Stage Biopharmaceutical Company Focused On Developing Innovative Biologic Therapeutics For Life Threatening Conditionsfounded In 2010 And Based In La Jollacaliforniathe Company Underwent A Significant Transformation In 2024 When It Spun Off From Its Parent Companyinhibrxincthe Company Is Advancing Several Therapeutic Candidatesincluding Inbrx 109Which Targets Death Receptor 5 For Treating Unresectable Or Metastatic Conventional Chondrosarcomaand Inbrx 106Aimed At Various Cancers Through Targeting Ox40Inhibrx Utilizes A Scalable Platform That Supports Adaptable And Targeted Therapiesensuring High Affinityspecificityand Stabilitywith A Dedicated Leadership Teamincluding Ceo Mark Lappeinhibrx Is Committed To Addressing Critical Unmet Medical Needs Through Its Innovative Pipeline
No conferences found for this company.
| Company Name | Inhibrx Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
